Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -5.16
- Piotroski Score 2.00
- Grade Buy
- Symbol (XFOR)
- Company X4 Pharmaceuticals, Inc.
- Price $0.34
- Changes Percentage (-6.92%)
- Change -$0.03
- Day Low $0.33
- Day High $0.37
- Year High $1.60
X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase Ib clinical trial to treat chronic neutropenia and Waldenström macroglobulinemia. The company is also developing X4P-002, a CXCR4 antagonist for the treatment of brain cancers; and X4P-003, a CXCR4 antagonist for the treatment of CXCR4 disorders and primary immunodeficiencies. It has a license agreement with Abbisko Therapeutics Co., Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company was founded in 2010 and is headquartered in Boston, Massachusetts.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 03/13/2025
- Fiscal Year End N/A
- Average Stock Price Target $3.00
- High Stock Price Target $5.00
- Low Stock Price Target $3.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$0.67
- Trailing P/E Ratio -1.51
- Forward P/E Ratio -1.51
- P/E Growth -1.51
- Net Income $-101,167,000
Income Statement
Quarterly
Annual
Latest News of XFOR
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
X4 Pharmaceuticals Inc (XFOR) Q3 2024 Earnings Call Highlights: Strategic Engagement and ...
Lower G-CSF usage involves a 25% reduction in dose and/or frequency, tailored to each patient's response. Phase three trials focus on FDA approval requirements, with future studies analyzing benefits ...
By Yahoo! Finance | 1 week ago -
It's Hague v Mandelson for the Oxford chancellorship - but do students care?
The election of the new chancellor at the University of Oxford, an 800-year-old position, is underway. Notable candidates include Peter Mandelson and William Hague. While students show varying levels ...
By The Guardian | 2 weeks ago -
Ashmolean Museum raises £4.8m to keep rare Fra Angelico work in Oxford
The Ashmolean Museum in Oxford raised £4.48m to keep Fra Angelico's The Crucifixion in the UK, preventing it from being sold to an overseas buyer....
By The Guardian | 2 weeks ago
